These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 18991816)

  • 1. [Effect of strict glycemic control on clinical state and course of the disease in patients with chronic heart failure and type II diabetes mellitus. Results of the REMBO "rational effective multicomponent therapy in the struggle against diabetes mellitus in patients with congestive heart failure" study].
    Lapina IuV; Filatov DN; Mareev VIu; Narusov OIu; Bolotina MG; Shestakova MV; Masenko VP; Litonova GN; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(9):17-27. PubMed ID: 18991816
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy and safety of the use of metformin in patients with chronic heart failure and type 2 diabetes mellitus. results of the study "rational effective mulicomponent therapy in the battle against diabetes mellitus in patients with chronic heart failure"].
    Lapina IuV; Narusov OIu; Mareev VIu; Bolotina MG; Shestakova MV; Masenko VP; Litonova GN; Arzamastseva NE; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(3):58-68. PubMed ID: 18429758
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of Sadko-CHF study)].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(8):14-20. PubMed ID: 17078211
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Is triple combination of different neurohormonal modulators recommended for treatment of mild-to-moderate congestive heart failure patients? (Results of SADKO-CHF study). Part 2].
    Skvortsov AA; Mareev VIu; Nasonova SN; Sychev AV; Arbolishvili GN; Baklanova NA; Masenko VP; Belenkov IuN
    Ter Arkh; 2006; 78(9):61-71. PubMed ID: 17076227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Efficacy and safety of long-term application of spironolactone in patients with moderate and severe chronic heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VY; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2007; 47(10):12-23. PubMed ID: 18260939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Effect of long term therapy with spironolactone on parameters of 24-hour heart rhythm variability and ventricular arrhythmias in patients with heart failure receiving optimal therapy].
    Skvortsov AA; Mareev VIu; Orlova IaA; Chelmakina SM; Baklanova NA; Belenkov IuN
    Kardiologiia; 2008; 48(2):52-64. PubMed ID: 18261010
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Influence of chronic cardiac failure severity on the course of comorbid type 2 diabetes mellitus].
    Narusov OIu; Lapina IuV; Mareev VIu; Bolotina MG; Shestakova MV; Masenko VP; Baklanova NA; Belenkov IuN
    Ter Arkh; 2009; 81(9):52-7. PubMed ID: 19827654
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of a randomized trial to test the safety and non-inferiority of canagliflozin in patients with diabetes with chronic heart failure: the CANDLE trial.
    Tanaka A; Inoue T; Kitakaze M; Oyama J; Sata M; Taguchi I; Shimizu W; Watada H; Tomiyama H; Ako J; Sakata Y; Anzai T; Uematsu M; Suzuki M; Eguchi K; Yamashina A; Saito Y; Sato Y; Ueda S; Murohara T; Node K
    Cardiovasc Diabetol; 2016 Apr; 15():57. PubMed ID: 27044332
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effect of the optimal neurohormonal blockade on long-term survival in patients with chronic heart failure].
    Roik M; Starczewska MH; Stawicki S; Huczek Z; Kochanowski J; Oreziak A; Furmańczyk A; Opolski G
    Pol Arch Med Wewn; 2006 Apr; 115(4):321-8. PubMed ID: 17078490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Glycemic control and clinical outcomes in diabetic patients with heart failure and reduced ejection fraction: insight from ventricular remodeling using cardiac MRI.
    Shi K; Zhang G; Fu H; Li XM; Gao Y; Shi R; Xu HY; Li Y; Guo YK; Yang ZG
    Cardiovasc Diabetol; 2024 Apr; 23(1):148. PubMed ID: 38685007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of angiotensin-converting enzyme inhibitor alone and in combination with irbesartan for the treatment of heart failure.
    Kum LC; Yip GW; Lee PW; Lam YY; Wu EB; Chan AK; Fung JW; Chan JY; Zhang Q; Kong SL; Yu CM
    Int J Cardiol; 2008 Mar; 125(1):16-21. PubMed ID: 17433840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel possibilities in the treatment of patients with heart failure. The method of external counterpulsation].
    Gabrusenko SA; Malakhov VV; Sergienko IV; Bugriĭ ME; Saidova MA; Kukharchuk VV; Belenkov IuN
    Kardiologiia; 2008; 48(9):10-6. PubMed ID: 18991815
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Clinical, hemodynamic and neurohumoral effects of switching patients with chronic heart failure from not recommended -adrenoblockers to bisoprolol in ambulatory practice].
    Ageev FT; Zhubrina ES; Ovchinnikov AG; Seredenina EM
    Kardiologiia; 2010; 50(6):41-7. PubMed ID: 20659026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of combined candesartan and ACE inhibitors on BNP, markers of inflammation and oxidative stress, and glucose regulation in patients with symptomatic heart failure.
    White M; Lepage S; Lavoie J; De Denus S; Leblanc MH; Gossard D; Whittom L; Racine N; Ducharme A; Dabouz F; Rouleau JL; Touyz R
    J Card Fail; 2007 Mar; 13(2):86-94. PubMed ID: 17395047
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of telmisartan added to Angiotensin-converting enzyme inhibitors on mortality and morbidity in hemodialysis patients with chronic heart failure a double-blind, placebo-controlled trial.
    Cice G; Di Benedetto A; D'Isa S; D'Andrea A; Marcelli D; Gatti E; Calabrò R
    J Am Coll Cardiol; 2010 Nov; 56(21):1701-8. PubMed ID: 21070920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long term prognosis of chronic heart failure: reduced vs preserved left ventricular ejection fraction.
    Miyagishima K; Hiramitsu S; Kimura H; Mori K; Ueda T; Kato S; Kato Y; Ishikawa S; Iwase M; Morimoto S; Hishida H; Ozaki Y
    Circ J; 2009 Jan; 73(1):92-9. PubMed ID: 19043227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with congestive heart failure: an observational study of treatment rates and clinical outcome.
    Gotsman I; Rubonivich S; Azaz-Livshits T
    Isr Med Assoc J; 2008 Mar; 10(3):214-8. PubMed ID: 18494235
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Glucose and insulin abnormalities relate to functional capacity in patients with congestive heart failure.
    Suskin N; McKelvie RS; Burns RJ; Latini R; Pericak D; Probstfield J; Rouleau JL; Sigouin C; Solymoss CB; Tsuyuki R; White M; Yusuf S
    Eur Heart J; 2000 Aug; 21(16):1368-75. PubMed ID: 10952826
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BNP and ANP as diagnostic and predictive markers in heart failure with left ventricular systolic dysfunction.
    Falcão LM; Pinto F; Ravara L; van Zwieten PA
    J Renin Angiotensin Aldosterone Syst; 2004 Sep; 5(3):121-9. PubMed ID: 15526247
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ADEPT: Addition of the AT1 receptor antagonist eprosartan to ACE inhibitor therapy in chronic heart failure trial: hemodynamic and neurohormonal effects.
    Murdoch DR; McDonagh TA; Farmer R; Morton JJ; McMurray JJ; Dargie HJ
    Am Heart J; 2001 May; 141(5):800-7. PubMed ID: 11320369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.